IP Library › Granted Patent US 12,398,203
Granted Patent B2
US 12,398,203 · App. 18/079,307 · Granted Aug 26, 2025

Method for producing bispecific antibodies comprising a Y436A Fc-region mutation for improved protein A-binding

Inventor: Tilman Schlothauer (Penzberg, DE)
C07K16/22A61K9/0019A61K9/0048A61K39/3955A61K39/40A61K45/06C07K16/1271A61K2039/505C07K2317/31C07K2317/33C07K2317/524C07K2317/526C07K2317/53C07K2317/54C07K2317/64C07K2317/71C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,398,203
App. No.
18/079,307
Granted
Aug 26, 2025
Kind
B2
Abstract

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first, the second, or the first and the second polypeptide comprise the mutation Y436A (numbering according to the EU index).

Claims (44)

1. A method for producing a bispecific antibody comprising a first polypeptide and a second polypeptide each comprising, in N-terminal to C-terminal direction, at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain,

wherein the first and/or the second polypeptide comprise the mutation Y436A (numbering according to Kabat), and wherein the antibody is a full-length antibody with a human IgG1 Fc-region (numbering according to Kabat), comprising the steps of:

a) cultivating a mammalian cell comprising one or more nucleic acids encoding the bispecific antibody,

b) recovering the bispecific antibody from the cultivation medium, and

c) purifying the bispecific antibody with a protein A affinity chromatography and thereby producing the bispecific antibody.

2. The method according to claim 1 , wherein the antibody is a monoclonal antibody.

3. The method according to claim 1 , wherein the antibody is a human, humanized or chimeric antibody.

4. The method according to claim 1 , wherein the antibody is a bivalent antibody.

5. The method according to claim 1 , wherein the antibody does not specifically bind to the human FcRn and does specifically bind to Staphylococcal protein A.

6. The method according to claim 1 , wherein

i) the first polypeptide is selected from the group comprising

human IgG1 Fc-region polypeptide,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A,

human IgG1 Fc-region polypeptide with the mutations Y349C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations S354C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, Y349C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, S354C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations P329G,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G,

human IgG1 Fc-region polypeptide with the mutations P329G, Y349C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations P329G, S354C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, Y349C, T366S, L368A, Y407V,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, S354C, T366S, L368A, Y407V,

human IgG1 with the mutations K392D, and

ii) the second polypeptide is selected from the group comprising

human IgG1 Fc-region polypeptide,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A,

human IgG1 Fc-region polypeptide with the mutations S354C, T366W,

human IgG1 Fc-region polypeptide with the mutations Y349C, T366W,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, S354C, T366W,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, Y349C, T366W,

human IgG1 Fc-region polypeptide with the mutations P329G,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G,

human IgG1 Fc-region polypeptide with the mutations P329G, S354C, T366W,

human IgG1 Fc-region polypeptide with the mutations P329G, Y349C, T366W,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, S354C, T366W,

human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, Y349C, T366W,

human IgG1 with the mutations D399K, D356K, and/or E357K.

7. The method according to claim 1 , wherein

i) the first Fc-region polypeptide is a human IgG1 Fc-region polypeptide and the second Fc-region polypeptide is a human IgG1 Fc-region polypeptide, or

ii) the first Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A and the second Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, or

iii) the first Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G and the second Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, or

iv) the first Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, S354C, T366W and the second Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, Y349C, T366S, L368A, Y407V, or

v) the first Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, S354C, T366W and the second Fc-region polypeptide is a human IgG1 Fc-region polypeptide with the mutations L234A, L235A, P329G, Y349C, T366S, L368A, Y407V.

Priority Claims (2)
EP 1415322 · Jan 15, 2014 · regional
EP 14165924 · Apr 25, 2014 · regional
Continuity (4)
Continuation 16244378 · Jan 10, 2019
Division 15210464 · Jul 14, 2016
Continuation PCTEP2015050389 · Jan 2, 2015
Related Publication 20230183330A1 · Jun 15, 2023
References Cited (44)
US 7923538B2 · Shitara et al. · 2011 [cited by applicant]
US 9217880B2 · Pugh et al. · 2015 [cited by applicant]
US 10195262B2 · Wacker et al. · 2019 [cited by applicant]
US 10316092B2 · Yao et al. · 2019 [cited by applicant]
US 20070219133A1 · Lazar · 2007 [cited by examiner]
US 20090162360A1 · Klein · 2009 [cited by examiner]
US 20100272720A1 · Lo · 2010 [cited by examiner]
US 20160231320A1 · Young et al. · 2016 [cited by applicant]
BR 102016022721A2 · 2018 [cited by applicant]
CA 3159061A1 · 2013 [cited by applicant]
EP 1601697B1 · 2007 [cited by applicant]
WO 9734631A1 · 1997 [cited by applicant]
WO 2005077981A2 · 2005 [cited by applicant]
WO WO2011008517A2 · 2011 [cited by applicant]
WO 2012069557A1 · 2012 [cited by applicant]
WO 2012093125A1 · 2012 [cited by applicant]
WO 2013056233A1 · 2013 [cited by applicant]
WO 2013063702A1 · 2013 [cited by applicant]
WO 2013166594A1 · 2013 [cited by applicant]
WO WO2014006217A1 · 2014 [cited by examiner]
WO 2015057668A1 · 2015 [cited by applicant]
Hober S,e t al. (2007) Journal of Chromatography B, 848:40-47. (doi:10.1016/j.jchromb.2006.09.030). [cited by examiner]
The English translation of the Chinese Office Action, mailed on Aug. 28, 2023, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
The US Office Action, mailed on Sep. 22, 2023, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The English translation (Google Translate) of the Argentina Office Action, mailed on Dec. 22, 2023, in related Argentina Application No. 20140101718. [cited by applicant]
US Office Action, mailed on Feb. 16, 2024, in related U.S. Appl. No. 16/590,938. [cited by applicant]
The Third Party Observations, posted on Dec. 1, 2023, in the related European Patent Appl. No. 15700545.5. [cited by applicant]
The Chinese Office Action, mailed on Feb. 27, 2023, in the related Chinese Patent Appl. No. 201911344011.0. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Nov. 25, 2022, in the related Chinese Patent Appl. No. 201911266804.5. [cited by applicant]
The US Office Action, mailed on Dec. 30, 2022, in the related U.S. Appl. No. 16/590,938. [cited by applicant]
The US Office Action, mailed on Jan. 12, 2023, in the related U.S. Appl. No. 15/947,377. [cited by applicant]
DeLano et al., “Convergent Solutions to Binding at a Protein-Protein Interface,” Science, 287:1279-1283, Feb. 18, 2000. [cited by applicant]
Jansson et al., “All individual domains of staphylococcal protein A show Fab binding,” FEMS Immunology and Medical Microbiology 20 (1998) 69-78. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jan. 24, 2024, in the related Chinese Patent Appl. No. 202110445639.0. [cited by applicant]
US Office Action, mailed on Mar. 13, 2024, in related U.S. Appl. No. 17/373,062. [cited by applicant]
The International Search Report and Written Opinion, mailed on Apr. 28, 2015, in related International Patent application No. PCT/EP2015/050425. [cited by applicant]
The English translation of the Chinese Office Action, mailed on Jul. 8, 2023, in the related Chinese Patent Appl. No. 201480024044.6. [cited by applicant]
The US Office Action, mailed on Jul. 5, 2023, in the related U.S. Appl. No. 16/590,938. [cited by applicant]
The US Office Action, mailed on Aug. 31, 2023, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
The English translation of the Japanese Office Action, mailed on Aug. 29, 2023, in the related Japanese Patent Appl. No. 2022-010878. [cited by applicant]
The US Office Action, mailed on Sep. 23,2024, in the related U.S. Appl. No. 15/947,424. [cited by applicant]
The US Office Action, mailed on Jan. 16, 2025, in the related U.S. Appl. No. 17/373,062. [cited by applicant]
Tustian et al., “Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity,” MAbs May-Jun. 2016;8(4):828-38. [cited by applicant]
The English translation of the Reexamination Notification, mailed on Apr. 17, 2025, in the related Chinese Appl. No. 201480023252.4. [cited by applicant]